
How the assisted dying debate is dividing doctors as politicians prepare to vote on bill
There are few issues more controversial, more divisive.
Assisted dying polarises opinion.
But it's a difficult conversation that needs to be had because ultimately death affects us all.
Even if you are fortunate enough to never be directly impacted by an assisted death you will almost certainly be indirectly affected if the End of Life Bill passes into law.
It would be the biggest social change to British society many of us would ever see in our lifetimes.
And after patients and their immediate families, it's the country's doctors who will be the most affected by any change in the law.
Like society, the medical community is divided on the issue.
One senior doctor said: "It's like Brexit, but worse."
Another told me: "Emotions are running high".
These are the milder, reportable comments.
There is bitterness and mistrust. The deep-rooted anger leads to each side accusing the other of deliberately spreading misinformation, "what-iffery" and "shenanigans" in the lead-up to the final vote next week.
We asked two senior doctors to share their views on assisted dying with us and each other.
Dr Mark Lee is a consultant in palliative care.
"I have worked in this field for 25 years and looked after thousands of patients at the end of their lives. I am against the assisted dying bill because I believe it poses risks to patients, to families, to doctors and to palliative care."
'We can get this right'
Dr Jacky Davis is a consultant radiologist and a campaigner for assisted dying legislation in this country.
One of the arguments put forward by opponents of assisted dying is that Britain ranks highest among countries in its delivery of palliative care. And there is no need for such a radical change in end of life care.
It is not an argument Dr Davis accepts.
She said: "The status quo at the moment means a number of people are dying bad deaths every day. 300 million people around the world have access to assisted dying and more legislation is in the pipeline and no place that has taken up a law on assisted dying has ever reversed it. So we can learn from other places, we can get this right, we can offer people a compassionate choice at the end of life."
Most deaths in palliative care 'peaceful'
Dr Lee accepts palliative care has its limitations but this is a result of underfunding. This national conversation, he argues, is an opportunity to address some of those failings and improve end of life care.
"I think the NHS currently is not resourcing the situation enough to be able to provide the patients with the choice that they need to get the care that they needed and that is because they are not getting the choice and because palliative care is patchy. But in my day-to-day work, and I've worked in palliative care for 25 years, normal death is peaceful, comfortable, and does not involve people dying in pain."
"I absolutely agree with Mark," Dr Davis responded. "The vast majority of people will die a peaceful death and do not have the need for an assisted death. And I absolutely am with him that palliative care in this country has been treated abysmally. Nobody should have to hold a jumble sale in order to fund a hospice. That's terrible.
"What I didn't hear from Mark is, while the vast majority of people will die a peaceful death and have got nothing to fear facing death, there are people who have diagnoses where they know that they are likely to face a difficult death and will face a difficult death.
"What are you offering to the people who aren't going to die a peaceful death? And what are you offering to people who are so afraid that that's going to happen that they will take their own lives or will go abroad to seek an assisted death?"
Concerns about pressure on NHS
One important voice that has been missing from the national assisted dying debate is that of the NHS.
Senior leaders will not speak on the issue until the fate of the bill is decided. And its understandable why. It is not clear what role the health service would have if the bill passes.
0:32
Dr Lee warned that his NHS colleagues were "extremely worried", going further to say assisted dying would "break the NHS".
He added, that the country's already under-pressure hospice sector would struggle to cope with staff "walking away from the job if they are forced to be involved in any way".
Dr Davis refuses to accept these warnings, arguing that the challenge to the health service is being overstated.
"I think it's really important to take a step back and say this would be a very small number of deaths. And this is very small in terms of the other things that are coming through big drug discoveries, big new surgeries, all the rest of it this would be very small in terms in terms of money."
The two doctors did agree on one thing. That every patient is entitled to a pain free and dignified death.
1:12
Dr Lee said: "I look at the whites of the eyes of people every day with that. I stand in that place every day. And that is shameful that anyone in this day and age should die in that position. Jacky and I can agree on that. That is unacceptable. But it still doesn't justify the response that we meet suffering with killing someone, rather than addressing the needs that are in front of us."
Dr Davis responded by saying: "You say you've looked in the whites of patients' eyes at the end, and I'd say looking into the whites of patients eyes and listening to what they're asking for when they've been offered everything that you can offer them and they're still saying, 'I've had enough', then we should follow the example of other countries and say, 'we will help you'."
These are the two very divided opinions of two NHS doctors, but these are the same arguments that will be taking place in hospitals, hospices, offices, factories and living rooms across the country.
In about a week's time, it will be down to the politicians to decide.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Times
25 minutes ago
- Times
Just for One Day review — on stage and off, Geldof goes on the attack
How did Bob Geldof corral the world's biggest pop stars into making first Band Aid and then Live Aid happen? Seeing the real Sir Bob speak to the gala night crowd at the Shaftesbury Theatre at opening night made it all come into focus even more keenly than the sometimes powerful, sometimes goofy, sometimes earnest musical about the events of 1984 and 1985 that preceded it. Geldof was electric. His hair white yet shaggy, his clobber casual yet sharp, he first saluted the show itself for its essential accuracy, never mind his character being some 'cartoon arsehole … just saying 'f***', basically'. The actor Craige Els, who plays Geldof, is actually one of the show's big successes, stalking around all night in double denim with a hangdog expression and a can-do attitude. He's so good you almost forget he's not actually Bob Geldof. Oh, until the real thing comes on to enthuse about how the 10 per cent cut the Band Aid charity gets from ticket prices has already raised almost £1 million. And then moves on to attack the American president's decision to remove funding for USAid on February 1, claiming that since then '300,000 people have died because of Musk, because of Trump, because of Vance'. He chided Keir Starmer for cutting Britain's foreign aid budget too. 'But mainly,' he added, 'this is the most fun in the West End you're ever going to have.' On that point, let's quibble. Not because Just for One Day is a horror — this larky-cum-lyrical reinvention of Geldof and co's incredible achievements is tighter than it was when it opened last year at the Old Vic, and features some breathtaking moments of music. Yet it's at least as frustrating as it is inspiring. It's neither a straight jukebox retelling — much though it is fuelled by dozens of the songs played in London and Philadelphia on July 13, 1985 — nor quite its own thing, much though it presents everything through a modern prism. A young character, Jemma, notes the surfeit of white straight males on stage at Live Aid, but they are in the minority on stage at the Live Aid musical. It's all retold by Suzanne, who was at Wembley as an 18-year-old. Her 18-year-old, Jemma, is up for hearing mum's memories, dubious of the lyrics of Do They Know It's Christmas. Geldof puts paid to such 'white saviour' quibbles so swiftly it was barely worth raising them. Indeed, there is a simpler, probably better version of this show that just gets on with biffing out the hits of that day loud and proud and in period style. After all, the six-piece band on the riser upstage are as tremendous as Geldof (the real one) says they are. But no: like some theatrical Red Nose Day, Luke Sheppard's production and John O'Farrell's script are a bumpy blend of some funny routines, some unfunny routines and some strenuously serious routines. Geldof is a great impression, George Ure (no relation) is a lifelike Midge Ure, and Julie Atherton excels as a twin-set-and-pearly-wearing Margaret Thatcher, bursting into Elton John's I'm Still Standing. Beyond that, though, verisimilitude is verboten. The large multitasking chorus play the real-life characters in their own voices and sing the song extracts (really well) their own way. Fine, but when it's so bitty there is little time for the music to build up a head of steam, to feel better than second-hand. When it does — on an extended version of Message in a Bottle or My Generation, say, or when the Queen songs get the most out of the massed chorus of voices — it can take your breath away. Shame a rock musical doesn't trust more in the power of rock. ★★★☆☆ 150min Shaftesbury Theatre, London, to Jan 10,


Daily Mail
37 minutes ago
- Daily Mail
UK vaccine chiefs suspend newly approved jab for over 65s - reports of two deaths and 21 severe reactions
UK vaccine chiefs have suspended a newly approved jab from being given to people aged over 65, after reports of two deaths and 21 severe reactions. The vaccine protects against the potentially fatal Chikungunya virus, which is typically found in the subtropical regions of the Americas, Africa, Southeast Asia, India, the Pacific Region and increasingly in Europe. Although the virus isn't found in the UK, Britons can become infected while overseas and fall ill when they return home. While the jab, called IXCHIQ, is approved in the UK it has yet to be rolled out, so there are no immediate safety concerns, British regulators said. The suspension follows global reports of 23 serious adverse effects in older people, including two deaths. It followed two fatalities in the French island La Réunion—in the Indian Ocean—where a vaccination campaign is underway following a recent Chikungunya outbreak. One death involved an 84-year-old man who developed encephalitis—a swelling of the brain—after having an adverse reaction to the vaccine. The other was a 77-year-old man living with Parkinson's disease who reportedly began finding swallowing increasingly difficult after the jab. This is believed to have triggered aspiration pneumonia, a serious infection caused by food, saliva and/or vomit entering the lungs rather than the stomach. The European Medicines Agency, who are reviewing the chikungunya vaccine following the reports, has not yet revealed the time between the dead men receiving the jabs and their deaths. There are no changes in the recommendations for vaccination with IXCHIQ for people aged between 18 and 64. The vaccine is currently not approved for use in individuals with a weakened immune system as a result of disease or medical therapy. The decision by the Commission on Human Medicines (CHM) is a precautionary measure until a further safety review has been concluded. The Medicines and Healthcare products Regulatory Agency (MHRA) is working with the vaccine manufacturer Valneva. The majority of people infected with Chikungunya develop a sudden fever and severe pain in multiple joints. Other symptoms may include headache, muscle pain, joint swelling, or rash. The virus is spread to humans by bites from infected mosquitoes, but cannot be passed from person-to-person. Symptoms typically resolve within 7 to 10 days, and most patients make a full recovery. However, in some cases the joint pain and arthritis may persist for several months or even years. Occasional cases of eye, neurological and heart complications have been reported, as well as gastrointestinal complaints. A small number of people may develop a severe version of the disease, which can lead to multiple organ failure and death. Severe symptoms and deaths are rare and usually occur in young babies or elderly people with coexisting health problems. There is no specific antiviral treatment for Chikungunya but medications (such as paracetamol) for fever and pain can be used to alleviate these symptoms. There are currently two vaccinations which protect against the virus; IXCHIQ for those aged between 18 and 64 and Vimkunya for those 12 years and older. A recent outbreak in La Réunion has seen over 47,500 cases of the virus, with 12 fatalities. In 2024 there were 112 Chikungunya cases reported in England, Wales and Northern Ireland from travellers arriving to or returning to Britain—this was nearly one-and-a-half times the level recorded in the previous year.


The Independent
an hour ago
- The Independent
Parents whose sons are losing ability to walk face ‘nightmare' battle with NHS
Parents whose sons are losing the ability to walk have described the 'nightmare' battle they face with the NHS to access a free drug. The medicine givinostat can slow progress of Duchenne muscular dystrophy – keeping children on their feet for longer – and is being offered for free by a drug firm while it goes through the process of NHS approval. However, only some NHS trusts across the UK, and few in England, are giving the drug despite it being part of an early access programme since November. Families are now facing a 'cruel' postcode lottery over who gets the medicine and are in a race against time, according to the charity Duchenne UK. Some NHS trusts are refusing to supply the drug while others delay it by drawing up lists of who they think should get it first. NHS trusts say they need to pay for monitoring the drug – around £1,900 per year per patient – out of their own budget. In desperation, parents have met with Health Secretary Wes Streeting to try and speed up access. According to the Government, it is up to individual NHS trusts to decide whether to provide the drug. Duchenne UK is supporting families in their fight for givinostat, including Rosie and Pete Day, an investment manager, and their 10-year-old son Jasper, from Horsham, West Sussex. The Day family have twins Jasper and Arabella, aged 10, and two older daughters. Both Jasper and Arabella have Duchenne, with Arabella a carrier of the genetic disorder and Jasper the most affected, as the condition mostly affects boys. The drug, developed by ITF Pharma UK, is only being given under the early access programme to children who are still able to walk. Mrs Day told the PA news agency: 'We try and live in the moment and, in this moment, there's an opportunity to make a massive change to Jasper. 'We're not going to cure it, but this drug gives him the best chance of having the early life that he wants to have and what every parent wants to give their child. 'It's so close – and yet we're stuck. 'We're stuck in this process where there's something in reaching distance that could make a huge difference to keep him walking, keep him active, keep him with his siblings in the garden, keep him walking up the stairs, all of those things, and it just feels that we can't quite get there. 'We're on the finishing line to get something that will make a difference and we can't quite get there because of the system we're in. 'The drug is not going to cure it, but it will give him the childhood you would wish to give your child – to keep them playing football, coming on dog walks, being able to walk up the stairs, playing the French horn, all of those things that you dream your child is going to get to do. 'We can't give it because it we're stuck, even though it's free and it's there – we can't give it. 'It feels like a nightmare, because you know that the doctors want to give it, but when it comes to getting the drug in his mouth and seeing what it would do, we're stuck. 'It's a lottery, basically, depending on where you are in the country … and within NHS trusts themselves.' Jasper is under the care of the Evelina London Children's Hospital, which is only now starting to contact patients and is drawing up a priority list for who gets the drug first. 'Every day that passes by is a day that we can see Jasper decline and see him struggling with his muscles,' Mrs Day said. 'Two weeks ago, he asked me, 'When will I get the drug, mummy?' 'We're stuck in a situation over who's going to make those decisions regarding who gets the drug – of whether Jasper gets it or another boy. 'For every boy it's heartbreaking, because someone ultimately is not going to get the drug at that moment based on the current criteria.' She added: 'If Jasper stops walking, we're not going to get that back. 'Every day matters. Six months ago, Jasper could walk up and down the stairs easily. He can't do that now and Pete has to push him up the stairs every night. 'Yet we can't give him something that is as simple as two spoons full of medicine and a blood test, and a little bit of maybe resource looking at the blood test results – that is what is standing in our way.' Mrs Day said it was unclear how the Evelina is 'going to make a fair choice' because knowing who will lose mobility is not an exact science. Mr Day said the process is 'hugely subjective' because there is no linear decline in the condition and the decisions made by NHS trusts could end up being 'completely wrong'. According to Duchene UK, boys whose condition is getting worse risk falling off the list entirely while waiting for the drug. Around 500 boys in the UK are eligible for givinostat, which can be taken at home like Calpol, with hospitals then doing follow-up blood tests of around eight in the first year, followed by twice a year thereafter. Children may also need an ECG, though these are already part of routine Duchenne monitoring. Emily Reuben and Alex Johnson, founders of Duchenne UK, said: 'As time ticks by, more boys are losing out on their chance to access givinostat. 'This is a simple treatment, which can be easily managed at home, and requires uncomplicated blood tests to monitor. It's free to the NHS and could offer real hope for patients and their families. 'The delays are cruel and the postcode lottery is unjustifiable. We are calling on the NHS to urgently make this available to both ambulant (walking) and non-ambulant boys.' To date, all health boards in Scotland are rolling out the drug, alongside those in Swansea and Cardiff. Leicester Royal Infirmary was the first trust in England to give the drug, but the Evelina has not yet, and neither have trusts in Manchester, Liverpool and Newcastle. Great Ormond Street Hospital is working to supply the drug. A spokesman for the Evelina said: 'We have begun contacting families of all existing Evelina London patients who may be eligible for givinostat and are working to set up appointments in the next few months. 'Our clinical team are working through our patient lists and are currently prioritising children who need the treatment most urgently, or are at a higher risk of losing movement (ambulation) soon.' An NHS spokesman said: 'The first National Institute for Health and Care Excellence (Nice) committee meeting to consider this treatment is scheduled to be held in July 2025, and if manufacturer ITF Pharma can offer a cost-effective price to enable Nice to recommend its use, the NHS will be ready to work with the company to explore fast-tracking access for patients. 'NHS England has published guidance on manufacturer-led early access schemes, which require trusts to cover substantial costs and find additional clinical resources to administer new treatments, and we understand a number of trusts across the country are preparing to offer givinostat via such a scheme.'